French pharmaceutical firm Servier announced on November 3, 2026, that its experimental drug sevasemten failed to slow disease progression in the pivotal Phase 3 GRAND CANYON study for Becker muscular dystrophy. Just five months after acquiring the drug from Edgewise Therapeutics for $1.55 billion upfront cash plus $1 billion in potential milestones, the trial failure poses a setback for Servier and for patients who currently have no approved treatments.
Sevasemten Phase 3 trial failure
- ▪Servier announced on November 3, 2026 that it is conducting a comprehensive analysis of the GRAND CANYON study dataset alongside prior clinical data to understand the Phase 3 results
- ▪Servier's experimental drug sevasemten failed to slow Becker muscular dystrophy compared to placebo in the pivotal Phase 3 GRAND CANYON study announced on November 3, 2026
Servier acquisition of Edgewise drug
- ▪Servier's $1.55 billion acquisition of sevasemten failed its pivotal trial five months after the June 2026 deal with Edgewise Therapeutics was struck
- ▪Servier purchased the experimental drug sevasemten from Edgewise Therapeutics in June 2026 for $1.55 billion in upfront cash, plus up to approximately $1 billion in potential milestones
Becker muscular dystrophy treatment landscape
- ▪Patients with Becker muscular dystrophy, a rare form of muscular dystrophy, currently have no approved treatments available
- ▪The Phase 3 GRAND CANYON trial failure of sevasemten represented a significant setback for both Servier and Becker muscular dystrophy patients seeking treatment options
Prior clinical study results discrepancy
- ▪The experimental drug sevasemten, originally developed by Edgewise Therapeutics, had previously demonstrated promising results in a smaller randomized clinical study conducted before Servier's 2026 acquisition of the drug
- ▪Servier stated on November 3, 2026 that the Phase 3 GRAND CANYON study results were not aligned with certain findings observed in earlier clinical studies of sevasemten conducted before Servier's 2026 acquisition of the drug
Story comments
Loading comments…